ArticleDrugs & aging2016
Angiotensin-Converting Enzyme Inhibitors and Parameters of Sarcopenia: Relation to Muscle Mass, Strength and Function: Data from the Berlin Aging Study-II (BASE-II).
Article in Drugs & aging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Pharmacological Interventions to Improve Muscle Mass, Muscle Strength and Physical Performance in Older People: An Umbrella Review of Systematic Reviews and Meta-analyses.Drugs & aging · 2018Pooled it
- Effect of angiotensin-converting enzyme inhibition on cardiovascular adaptation to exercise training.Physiological reports · 2022Trial
- Effect of Antihypertensive and Statin Medication Use on Muscle Performance in Community-Dwelling Older Adults Performing Strength Training.Drugs & aging · 2021Trial
- Long-term intake of statins or renin-angiotensin system inhibitors: associations with sarcopenia-related parameters in older people.GeroScience · 2026Article
- Vascular and musculoskeletal interactions: structure, function, and therapeutic strategies for sarcopenia and osteoporosis.MedScience · 2026Review
- Comparing fourteen consensus biomarkers of aging: epigenetic pace of aging as the strongest predictor of mortality in BASE-II.Biomarker research · 2026Article
- Renin angiotensin system-induced muscle wasting: putative mechanisms and implications for clinicians.Molecular and cellular biochemistry · 2025Review
- Is sarcopenia an associated factor of increased administration of specific medications in patients with heart failure? A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2024Review
- Associations Between Hypertension, Angiotensin-Converting Enzyme Inhibitors, and Physical Performance in Very Old Adults: Results from the ilSIRENTE Study.The Journal of frailty & aging · 2024Article
- Sarcopenia and nervous system disorders.Journal of neurology · 2022Review
- Rewinding sarcopenia: a narrative review on the renin-angiotensin system.Aging clinical and experimental research · 2021Review
- Does renin-angiotensin system inhibition have impacts on muscle mass and bone mineral density in heart failure patients?ESC heart failure · 2021Article
- Effects of Functional Training on Sarcopenia in Elderly Women in the Presence or Absence of ACE Inhibitors.International journal of environmental research and public health · 2021Article
- Relationship Between Sarcopenia and Cardiovascular Diseases in the Elderly: An Overview.Frontiers in cardiovascular medicine · 2021Review
- Muscle Wasting and Sarcopenia in Heart Failure-The Current State of Science.International journal of molecular sciences · 2020Review
- Multimodal Intervention to Improve Functional Status in Hypertensive Older Adults: A Pilot Randomized Controlled Trial.Journal of clinical medicine · 2019Article
- Thermodilution vs estimated Fick cardiac output measurement in an elderly cohort of patients: A single-centre experience.PloS one · 2019Article
- Hypertension and frailty in older adults.Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
- Is cardiac wasting accompanied by skeletal muscle loss in breast cancer patients receiving anticancer treatment?Journal of cachexia, sarcopenia and muscle · 2017Article
- ACE Inhibitors and Sarcopenia: Covering All the BASEs?Drugs & aging · 2016Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPharmacological options for the treatment of sarcopenia currently do not exist. However, off-label treatment options of some established drugs have been suggested.
objectivesThe aim of this study was to assess differences in various muscle and physical performance parameters in relation to the intake of angiotensin-converting enzyme (ACE) inhibitors in a cohort of community-dwelling older people.
methodsEight hundred and thirty-eight participants from the Berlin Aging Study-II (BASE-II) were included. Appendicular lean mass was assessed with dual-energy X-ray absorptiometry and related to height and body mass index. Muscle strength was measured by grip strength and related to muscle mass (arm muscle quality) and functional status was assessed via the timed "Up and Go" test.
resultsUsers of ACE inhibitors had higher lean mass related to height but significantly lower lean mass related to body mass index (p = 0.001 for women and p < 0.0001 for men). Moreover, they exhibited lower arm muscle quality (p = 0.032 for women and p = 0.031 for men) and reported difficulties in climbing stairs more often than non-users (p = 0.014 for women and p = 0.004 for men). After adjustment for confounders, there were no significant differences regarding lean mass, arm muscle quality and the timed "Up and Go" test according to the use of ACE inhibitors.
conclusionsIn BASE-II, no positive relationship was found between the intake of ACE inhibitors and lean mass, strength, muscle quality or function. Moreover, remarkable differences between parameters of absolute and relative lean mass in relation to the use of ACE inhibitors became evident. Fat mass proved to be an important confounder and therefore muscle mass cannot be viewed irrespectively of whole body composition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.